104 related articles for article (PubMed ID: 15493218)
21. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
Montalescot G; Walenga JM
Clin Appl Thromb Hemost; 2009; 15(2):183-96. PubMed ID: 19117960
[TBL] [Abstract][Full Text] [Related]
22. Novel oral anticoagulants and diet: the potential for interaction.
Kamali F
Am J Hematol; 2009 Apr; 84(4):260-1. PubMed ID: 19253346
[No Abstract] [Full Text] [Related]
23. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
24. A replacement for warfarin: the search continues.
Eikelboom JW; Weitz JI
Circulation; 2007 Jul; 116(2):131-3. PubMed ID: 17576860
[No Abstract] [Full Text] [Related]
25. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
26. New oral anticoagulants in atrial fibrillation.
Turpie AG
Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
[TBL] [Abstract][Full Text] [Related]
27. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
28. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
[TBL] [Abstract][Full Text] [Related]
29. Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency.
Oram MP; Mumford AD; Morse C; Underwood S
J Cardiothorac Vasc Anesth; 2006 Aug; 20(4):580-2. PubMed ID: 16884995
[No Abstract] [Full Text] [Related]
30. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
Ammollo CT; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
[No Abstract] [Full Text] [Related]
31. [Heparinemia (anti-factor Xa activity].
Emile C
Rev Infirm; 2007 Nov; (135):49-50. PubMed ID: 18159695
[No Abstract] [Full Text] [Related]
32. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
33. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
[TBL] [Abstract][Full Text] [Related]
34. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
[TBL] [Abstract][Full Text] [Related]
35. Sulfonamidolactam inhibitors of coagulation factor Xa.
Smallheer JM; Wang S; Laws ML; Nakajima S; Hu Z; Han W; Jacobson I; Luettgen JM; Rossi KA; Rendina AR; Knabb RM; Wexler RR; Lam PY; Quan ML
Bioorg Med Chem Lett; 2008 Apr; 18(7):2428-33. PubMed ID: 18329876
[TBL] [Abstract][Full Text] [Related]
36. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
37. Homogeneous sulfation of bagasse cellulose in an ionic liquid and anticoagulation activity.
Wang ZM; Li L; Xiao KJ; Wu JY
Bioresour Technol; 2009 Feb; 100(4):1687-90. PubMed ID: 18973999
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
39. A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.
McBride BF
J Clin Pharmacol; 2005 Sep; 45(9):1004-17. PubMed ID: 16100294
[TBL] [Abstract][Full Text] [Related]
40. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
